No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
GlycoMimetics Merger-Bound Crescent Appoints Joshua Brumm As CEO
Crescent Biopharma Appoints Joshua Brumm as Chief Executive Officer and Expands Leadership Team to Advance Pipeline of Potentially Best-in-Class Oncology Therapeutics
Cantor Fitzgerald Initiates GlycoMimetics(GLYC.US) With Buy Rating
GlycoMimetics Analyst Ratings
Cantor Fitzgerald Initiates GlycoMimetics at Overweight
Express News | GlycoMimetics : Following Termination, Co Will Not Have Any Material Financial or Other Obligations Under Agreement